CLC bio continues success with a 30 percent growth in software sales and over 500 new organizations as customers in 2012
Aarhus, Denmark -- February 12, 2013 -- Today, the world’s leading bioinformatics software company, CLC bio, is pleased to announce a continued positive development in 2012 with a 30% increase in both software sales and employees, and more than a 30% rise in new organizations as customers.
Adding another 2.9 million US Dollars to the total income, CLC bio also joined two European Union funded FP7 projects, STATegra and PATHSEEK. In collaboration with some of the leading scientists in Europe, the company will provide their expertise and platform to develop novel ways of analyzing, comparing, and visualizing next generation sequencing data.
CLC bio is a privately owned company, primarily funded by local investors and successfully built without venture capital since January 2005. CLC bio is based in Aarhus, Denmark. CLC bio exports 98% of its software to organizations in countries outside of Denmark, and 50% of the sales are generated in the USA.
About CLC bio
Contact CLC bio
Lasse Görlitz, VP of Communications
Tel: +1 (617) 765 0687
- CLC Genomics Workbench
- CLC Main Workbench
- General Information